iShares Biotechnology ETF
419 hedge funds and large institutions have $6.6B invested in iShares Biotechnology ETF in 2015 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 134 increasing their positions, 150 reducing their positions, and 38 closing their positions.
71% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 38
27% more funds holding in top 10
Funds holding in top 10: 33 → 42 (+9)
5% more funds holding
Funds holding: 399 → 419 (+20)
0% less capital invested
Capital invested by funds: $6.62B → $6.6B (-$14.8M)
11% less repeat investments, than reductions
Existing positions increased: 134 | Existing positions reduced: 150
65% less call options, than puts
Call options by funds: $665M | Put options by funds: $1.9B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$72.8M |
| 2 |
Citigroup
New York
|
+$54.6M |
| 3 |
Millennium Management
New York
|
+$53.1M |
| 4 |
SG Americas Securities
New York
|
+$36.4M |
| 5 |
MAA
Managed Account Advisors
Jersey City,
New Jersey
|
+$35.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
Beaumont Financial Advisors
Needham,
Massachusetts
|
-$153M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$139M |
| 3 |
Goldman Sachs
New York
|
-$107M |
| 4 |
Morgan Stanley
New York
|
-$65.7M |
| 5 |
JP Morgan Chase
New York
|
-$60M |
IBB Hedge Fund Activity: Q2 2015 in Review
419 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q2 2015, worth a combined $6.6B — down 0.22% from $6.62B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new IBB positions and 38 closed out — a net gain of 27 holders — while 134 added to existing stakes and 150 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $72.8M. The largest seller was Beaumont Financial Advisors, cutting an estimated $153M.
- 419 institutional investors held iShares Biotechnology ETF (IBB) as of Q2 2015, up from 399 in Q1 2015.
- Funds reported $6.6B of iShares Biotechnology ETF stock for Q2 2015, down 0.22% quarter-over-quarter.
- 65 funds opened new iShares Biotechnology ETF positions in Q2 2015 and 38 closed out, a net change of +27 holders.
- The largest iShares Biotechnology ETF buyer in Q2 2015 was Citadel Advisors, an estimated $72.8M added.
- The largest iShares Biotechnology ETF seller in Q2 2015 was Beaumont Financial Advisors, an estimated $153M sold.
Based on aggregated 13F filings for Q2 2015.